Introduction
============

Chronic obstructive pulmonary disease (COPD) is a common respiratory condition characterized by airflow limitation [@B1] and airway and systemic inflammation. [@B2] Inflammation alone or combined with other factors influences cancer risk in humans [@B3]; the most common link between inflammation and cancer risk in COPD patients is aberrant inflammation and immunity. [@B4] COPD is primarily caused by smoking. However, COPD has been independently associated with an increased risk of lung cancer and is probably associated with the inflammation and scarring accompanying COPD development. [@B5], [@B6] In COPD patients, oxidized low-density lipoprotein (LDL) levels are high and are associated with lung function, inflammation, and oxidative stress. [@B7]

Lipid metabolism disorders are risk factors for several cancers.[@B8]-[@B10] In COPD patients, a common potential mechanism by which major risk factors such as smoking, hyperlipidemia, obesity, and hypertension lead to chronic diseases is systemic inflammation.[@B11], [@B12] A meta-analysis of 28 case-control studies and 17 observational cohort studies revealed an increased lung cancer risk associated with an affected relative risk of 1.8.[@B13] Taken together, COPD patients are at a high risk of cancers throughout their lives.

Statin therapy has various effects that may contribute to reducing the cancer risk, such as anti-inflammatory, antioxidant, and antiplatelet effects as well as lipid modification.[@B14]-[@B17] Reduced monocyte adhesion to the endothelium, reduced oxidative stress modification of LDLs, and increased mobilization and differentiation of endothelial progenitor cells also are potential benefits of lipid-lowering therapy.[@B18], [@B19] Thus, statins can be chemopreventive agents for COPD patients with chronic systemic inflammation and hyperlipidemia. Some meta-analyses of randomized trials have consistently revealed that statins do not affect cancer incidence and cancer mortality; however, this may be because of the selection of study populations that are not at a high cancer risk. [@B20], [@B21]

In this study, we evaluated the chemopreventive effects of statins against all cancers in COPD patients, who are at a high risk of cancer because of chronic systemic inflammation, hyperlipidemia, and higher oxidative stress. In addition, we investigated the dose-dependence of this chemopreventive effect and evaluated the potential of anticancer effects of different types of statins.

Patients and Methods
====================

The National Health Insurance (NHI) program, established in 1995, currently provides comprehensive health insurance coverage to 98% of the more than 23 million people in Taiwan. We used data from the NHI Research Database (NHIRD). Distributions of age, sex, and health care costs in the NHIRD and among NHI enrollees do not differ significantly. Data that can be used to identify patients or care providers, including the names of medical institutions and physicians, are encrypted before being sent to the National Health Research Institutes for inclusion in the NHIRD. The institutes further encrypt the data before releasing the database to researchers. Theoretically, the NHIRD data alone is insufficient to identify any individual. All researchers using the NHIRD and its data subsets must sign a written agreement declaring that they have no intention of attempting to obtain information that could potentially violate the privacy of patients or care providers. [@B22]

Our study cohort comprised all patients diagnosed with COPD (according to International Classification of Diseases, Ninth Revision, Clinical Modification \[ICD-9-CM\] codes) at health care facilities in Taiwan (n = 116,017) between January 1, 2001, and December 31, 2012. We excluded patients without a subsequent outpatient visit, emergency department visit, or inpatient hospitalization for COPD within 12 months of the first presentation (n = 48,212); these patients were considered to not have COPD (Fig [1](#F1){ref-type="fig"}). We also excluded 15,436 patients aged younger than 40 years (n = 52,369) and had any cancer-related inpatient or outpatient diagnoses before the index date (n = 5,353) or had been prescribed any statins within 6 months before the index date (n = 3,214).

Our final study cohort contained 43,802 patients diagnosed with COPD in Taiwan over the 11-year period; of these, 10,086 used statins and 33,716 did not (Table [1](#T1){ref-type="table"}). Each patient was followed to assess the risk and protective factors for all cancers. In addition, we considered factors such as demographic characteristics (age and sex); comorbidities (diabetes, hypertension, dyslipidemia) and the Charlson comorbidity index (CCI); urbanization level; monthly income; and the use of nonstatin lipid-lowering drugs, metformin, aspirin, and angiotensin-converting enzyme inhibitor (ACEI). The index date of statin use was the date of COPD confirmation. Because we aimed to evaluate the preventive effects of statin use in COPD patients having a high all-cancer risk, the primary endpoint was the all-cancer risk and the secondary endpoints were the differential benefits of various doses and types of statins. The defined daily dose (DDD)---recommended by the World Health Organization---is a measure of the prescribed drug amount. DDD is the assumed average maintenance dose per day of a drug consumed for its main indication in adults. [@B23] To examine the dose-response relationship, we categorized statin use into four groups in each cohort (\<28, 28-90, 91-365, and \>365 cumulative DDDs \[cDDDs\]) because the duration of the refill card was 3 months. Patients receiving \<28 cDDDs were defined as statin nonusers (Tables [2](#T2){ref-type="table"}-[4](#T4){ref-type="table"}). [@B24] Furthermore, to examine the preventive effect of different types of statins, we categorized statin use into different individual statin use groups in each cohort (Table [3](#T3){ref-type="table"}).

Propensity scores (PSs) were derived using a logistic regression model to estimate the effect of statins by accounting for the covariates predicting receiving the intervention (statins). This method is commonly used in observational studies to reduce selection bias. [@B25] The covariates in the main model were PS adjusted for age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income in New Taiwan dollars (NT\$0, NT\$1-21,000, NT\$21,000-33,300; and ≥NT\$33,301; Table [2](#T2){ref-type="table"}). The endpoint for both statin users and nonusers was the diagnosis of all cancers (ICD-9-CM 140-209) with a subsequent outpatient visit, emergency department visit, or inpatient hospitalization for any cancer within 12 months of diagnosis; the nonusers were used as the reference arm. The cumulative incidence of any cancer in the two groups was estimated using the Kaplan-Meier method.

A time-dependent Cox proportional hazard model was used to calculate the hazard ratios (HRs) of the all-cancer risk in the statin users and nonusers. The HRs were adjusted for age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income in the multivariate analysis. A stratified analysis was conducted to evaluate the effect of statin use on age and sex (Table [2](#T2){ref-type="table"}). All analyses were conducted using SAS software (Version 9.3; SAS, Cary, NC, USA); two-tailed *P* \< 0.05 was considered significant. In sensitivity analyses, external adjustments are used to improve the understanding of the effects of drugs and other covariates in epidemiological database studies. [@B26] Hence, in our sensitivity analyses, data were adjusted in different models to estimate the association of all-cancer incidence with age, sex, diabetes, dyslipidemia, hypertension, CCI, anxiety disorder, and the use of nonstatin lipid-lowering drugs, metformin, aspirin, and ACEI. The drug use-stratified models were adjusted for covariates in the main model and for each additional covariate (Table [4](#T4){ref-type="table"}).

Results
=======

Our COPD cohort comprised 43,802 patients; of these, 10,086 (30%) used statins and the remaining 33,716 (70%) did not (Table [1](#T1){ref-type="table"}). The total follow-up duration was 194,933.6 and 80,239.4 person-years for the statin nonusers and users, respectively. Compared with the statin nonusers, the statin users exhibited a higher prevalence of pre-existing medical comorbidities, such as diabetes, hypertension, and dyslipidemia, and a higher CCI (all *P* \< 0.001). In addition, significant differences were observed between the two groups in the distributions of age, sex, monthly income, and urbanization level as well as the use of nonstatin lipid-lowering drug, aspirin, ACEI, and metformin (Table [1](#T1){ref-type="table"}). A higher proportion of statin nonusers used nonstatin lipid-lowering drugs, metformin, ACEI, and aspirin for \<28 days; however, most statin users used these drugs for \>365 days. A lower proportion of statin nonusers had a monthly income of ≥NT\$33,301 or resided in urban areas. Table [2](#T2){ref-type="table"} shows the all-cancer risk among the statin nonusers and users. After PS adjustment for age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income, we analyzed the all-cancer risk. The adjusted HRs (aHRs) for the all-cancer risk were lower among the statin users than among the statin nonusers (aHR = 0.46, 95% confidence interval \[CI\]: 0.43 to 0.50). The stratified analysis showed that the aHRs were significantly lower in the statin users, particularly those aged 40-74 years, regardless of sex. Specifically, the aHRs for the all-cancer risk were lower in the statin users than in the statin nonusers for every age group (40-64, 65-74, and ≥ 75 years; aHRs = 0.43, 0.45, and 0.51, respectively). The statin users also exhibited lower aHRs for the all-cancer risk than the statin nonusers did, after sex stratification (women: aHR = 0.44, 95% CI: 0.40 to 0.50; men: aHR = 0.48, 95% CI: 0.43 to 0.52).

Statins dose-dependently reduced the all-cancer risk in different cDDD subgroups; the main model was PS adjusted for age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income (Table [3](#T3){ref-type="table"}). Lipophilia statins comprised simvastatin, lovastatin, atorvastatin, and fluvastatin, whereas hydrophilia statins comprised pravastatin and rosuvastatin. Table [3](#T3){ref-type="table"} presents the all-cancer risk reduction demonstrated by lipophilia and hydrophilia statins in patients with COPD along with the doses and responses (*P* for trend \< 0.001). Among individual statins, lovastatin did not reduce the all-cancer risk in patients with COPD significantly. The aHRs for the all-cancer risk in patients using rosuvastatin, simvastatin, atorvastatin, pravastatin, and fluvastatin were lower than those of statin nonusers (aHRs = 0.42, 0.55, 0.59, 0.66 and 0.78, respectively). Our results revealed that individual statins reduced the all-cancer risk at varying efficacies among COPD patients.

In the sensitivity analysis, PS adjustments were made to estimate the associations of age, sex, CCI, diabetes, hypertension, dyslipidemia, urbanization level, monthly income, and nonstatin lipid-lowering drugs, metformin, ACEI, and aspirin use with the incidence of all cancers in different models. Table [4](#T4){ref-type="table"} shows that the effects of statins remained significant in the subgroups of various covariates when the main model was adjusted for PSs. Statins dose-dependently reduced the all-cancer risk in all subgroups and the main model with additional covariates (nonstatin lipid-lowering drugs, metformin, ACEI, or aspirin use). All aHRs indicated that statins dose-dependently induced significant reductions in the all-cancer risk in all subgroups, regardless of comorbidities or drug use (*P* \< 0.001). Thus, our data revealed that statins show a dose-dependent chemopreventive effect against all cancers.

Discussion
==========

Recently, interest in the function of systemic inflammation in COPD has been increasing.[@B27]-[@B31] Epidemiological studies have shown that elevated levels of systemic inflammatory markers, particularly C-reactive protein (CRP), interleukin 6, and fibrinogen, predict poor outcomes in COPD, including accelerated lung function loss, stronger infective exacerbation propensity, and higher mortality.[@B32]-[@B34] The prevalence of smoking is considerably high among COPD patients: 54%-77% among mild COPD patients and 38%-51% among severe COPD patients.[@B35]-[@B38] A 25-year follow-up study of a general population in the Danish Death Register revealed that 92% of the COPD patients have a current or past history of smoking.[@B39] Smoking reduces the serum high-density lipoprotein (HDL)-cholesterol levels and impairs HDL function by reducing its antioxidant and anti-inflammatory capacity and impeding the cellular cholesterol efflux.[@B40], [@B41] Statins reduce CRP levels, independent of their effects on lipids,[@B42], [@B43] thus potentially preventing cancers among COPD patients with systemic inflammation and lipid disorder.

Cancers are the leading causes of death in Taiwan. [@B44] Age is a major risk factor for sporadic cancer. In this study, the strongest chemopreventive effect against all cancers was observed in COPD patients aged 40-75 years (Table [2](#T2){ref-type="table"}). Thus, in Taiwan, statins may have favorable chemoprevention effects in COPD patients at higher all-cancer risk owing to their age. After sex stratification, the aHRs in statin users were lower than statin nonusers (women: aHR = 0.55, 95% CI: 0.42 to 0.72; men: aHR = 0.44, 95% CI: 0.40 to 0.50). A similar effect of reduction in the all-cancer risk was observed among COPD patients, regardless of their sex.

In this study, statins reduced the all-cancer risk in COPD patients with dose-dependently regardless of lipophilia or hydrophilia statin use. This is the first article to estimate the dose-dependent chemopreventive effect of statins against all cancers in COPD patients. Hydrophilia statins (aHR = 0.45, 95% CI: 0.36 to 0.55) appeared to have a stronger potential anticancer effect because their moderate dose (91-365 cDDDs) could more sufficiently reduce cancer incidence compared with lipophilia statins (aHR = 0.65, 95% CI: 0.58 to 0.73). On estimating the chemopreventive effects of individual statins against all cancers, we observed the following: the aHRs for the all-cancer risk among patients using rosuvastatin, simvastatin, atorvastatin, pravastatin, and fluvastatin differed (aHRs = 0.42, 0.55, 0.59, 0.66, and 0.78, respectively). Individual statins reduced the all-cancer risk at varying efficacies among COPD patients. The anticancer efficacies of different statins may be compatible with their lipid-lowering ability. In our study, rosuvastatin had the most predominant chemoprevention effect against all cancers in COPD patients. Rosuvastatin, atorvastatin, and simvastatin also caused the highest percent change in LDL-cholesterol levels. Rosuvastatin is slightly more potent than is atorvastatin, and both these agents are significantly more potent than simvastatin, lovastatin, pravastatin, and fluvastatin.[@B45], [@B46] At maximal prescribed doses, the reduction in LDL levels is larger with rosuvastatin and atorvastatin than with the other available statins.[@B47] This study is the first to estimate the anticancer efficacies of statins and compatible with the potency of for lowering LDL levels. These outcomes can indicate a statin ideal for further clinical studies

A higher proportion of statins nonuser used nonstatin lipid-lowering drugs, metformin, ACEI, and aspirin for \<28 cDDDs; however, most statin users used these for ≥28 cDDDs. If moderate to high cDDDs (28-365 or \>365 cDDDs) of aspirin, metformin, and ACEI are used, the chemopreventive effect of statins against the all cancer risk will be masked (Table [4](#T4){ref-type="table"}). If statin dose is increased to \>365 cDDDs, the aHRs of statins for reducing all-cancer risk in COPD patients were significant in our sensitivity analysis. These outcomes might explain the independent chemopreventive effect of aspirin, metformin, ACEI, nonstatin lipid-lowering drugs, and statins.[@B48], [@B49] However, the anticancer effects of statins, associated with anti-inflammatory, antioxidant, antiplatelet, and lipid modification effects, cannot be replaced by aspirin, metformin, ACEI, and nonstatin lipid-lowering drug use.[@B14]-[@B16] This is also the first study to propose that statins exerts dose-response and chemopreventive effects against all cancers in COPD patients.

However, this study has potential limitations. The bias of additional risk factors associated with COPD and all cancers, including a personal or family history of sporadic cancers, obesity, alcohol use, physical activity, and smoking, could not be eliminated. A large-scale randomized trial with a suitable regimen in well-selected patients comparing standard approaches is required for obtaining this crucial information. However, methodological concerns may obscure the precise relationship between these factors and cancer risk. In our study, we used PSs to match age, sex, the CCI, diabetes, hypertension, dyslipidemia, urbanization levels, and monthly income. The urbanization level and monthly income are invalidated alternatives for lifestyle factors and the environmental level. Moreover, the diagnoses of all cancers and other comorbidities were completely dependent on the ICD-9-CM codes. Nevertheless, the NHI Administration randomly reviews medical records and interviews patients to validate diagnoses, and hospitals with outlier diagnoses and practices may be audited and subsequently penalized heavily if malpractice and discrepancies are discovered. Another limitation of this study is that information on several unmeasured confounders, such as body mass index, smoking, alcohol use, and other over-the-counter drug use---which are associated with cancers---is unavailable in the NHIRD. However, considering the magnitude and significance of the observed effects, it is unlikely that these limitations have compromised the results. Finally, because our study is not a prospective randomized blinded study, a cause-effect relationship could not be established. The findings of this study suggest that statins dose-dependently exert a significant chemopreventive effect against all cancers in COPD patients. Additional randomized studies are required to verify these findings.

Conclusions
===========

Statins dose-dependently exert a significant chemopreventive effect against all cancers in COPD patients; in particular, rosuvastatin has the strongest chemopreventive effect.
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###### 

Characteristics of the Sample Population.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                   Entire cohort\   Patients using statins (≥28 cDDDs; n = 10,086)   Patients not using statins (\<28 cDDDs; n = 33,716)   *P*^a^                    
                                   (n = 43,802)                                                                                                                                      
  -------------------------------- ---------------- ------------------------------------------------ ----------------------------------------------------- --------- ------- ------- ---------
  Age, years (mean ± SD)           62.92 (13.18)    61.55 (10.97)                                    63.33 (13.74)                                         \<0.001                   

  40-54                            14458            33.01                                            3180                                                  31.53     11278   33.45   \<0.001

  55-64                            9644             22.02                                            2899                                                  28.74     6745    20.01   

  65-74                            10455            23.87                                            2777                                                  27.53     7678    22.77   

  ≥75                              9245             21.11                                            1230                                                  12.20     8015    23.77   

  Sex                                                                                                                                                                                

  Female                           19715            45.01                                            5150                                                  51.06     14565   43.20   \<0.001

  Male                             24087            54.99                                            4936                                                  48.94     19151   56.80   

  CCI^+^                                                                                                                                                                             

  0                                11279            25.75                                            2586                                                  25.64     8693    25.78   \<0.001

  1                                12597            28.76                                            3014                                                  29.88     9583    28.42   

  2                                9075             20.72                                            2195                                                  21.76     6880    20.41   

  ≥3                               10851            24.77                                            2291                                                  22.71     8560    25.39   

  Diabetes                                                                                                                                                                           

  No                               33491            76.46                                            6819                                                  67.61     26672   79.11   \<0.001

  Yes                              10311            23.54                                            3267                                                  32.39     7044    20.89   

  Hypertension                                                                                                                                                                       

  No                               22067            50.38                                            4158                                                  41.23     17909   53.12   \<0.001

  Yes                              21735            49.62                                            5928                                                  58.77     15807   46.88   

  Dyslipidemia                                                                                                                                                                       

  No                               31731            72.44                                            5785                                                  57.36     25946   76.95   \<0.001

  Yes                              12071            27.56                                            4301                                                  42.64     7770    23.05   

  Nonstatin lipid-lowering drugs                                                                                                                                                     

  \<28 days                        39267            89.65                                            7212                                                  71.51     32055   95.07   \<0.001

  28-365 days                      3186             7.27                                             1923                                                  19.07     1263    3.75    

  \>365 days                       1349             3.08                                             951                                                   9.43      398     1.18    

  Metformin                                                                                                                                                                          

  \<28 days                        35961            82.10                                            6286                                                  62.32     29675   88.01   \<0.001

  28-365 days                      2684             6.13                                             964                                                   9.56      1720    5.10    

  \>365 days                       5157             11.77                                            2836                                                  28.12     2321    6.88    

  ACEI                                                                                                                                                                               

  \<28 days                        23928            54.63                                            3066                                                  30.40     20862   61.88   \<0.001

  28-365 days                      7925             18.09                                            1928                                                  19.12     5997    17.79   

  \>365 days                       11949            27.28                                            5092                                                  50.49     6857    20.34   

  Aspirin                                                                                                                                                                            

  \<28 days                        28319            64.65                                            4161                                                  41.26     24158   71.65   \<0.001

  28-365 days                      7385             16.86                                            2296                                                  22.76     5089    15.09   

  \>365 days                       8098             18.49                                            3629                                                  35.98     4469    13.25   

  Urbanization level                                                                                                                                                                 

  Urban                            30539            69.72                                            7208                                                  71.47     23331   69.20   \<0.001

  Suburban                         8914             20.35                                            1920                                                  19.04     6994    20.74   

  Rural                            4349             9.93                                             958                                                   9.50      3391    10.06   

  Monthly income (NT\$)                                                                                                                                                              

  0                                3464             7.91                                             795                                                   7.88      2669    7.92    \<0.001

  1-21000                          15001            34.25                                            3067                                                  30.41     11934   35.40   

  21000-33300                      12904            29.46                                            3165                                                  31.38     9739    28.89   

  ≥33301                           12433            28.38                                            3059                                                  30.33     9374    27.80   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

a Comparison between statin use and no statin use.

+CCI: Charlson comorbidity index.

###### 

All-Cancer Risk in Statin Users and Nonusers in the Study Cohort.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Entire cohort\        Patients not using statins\                 Patients using statins\                    aHR†\                                                    
  (n = 43,802)          (Total follow-up: 194,933.6 person-years)   (Total follow-up: 80,239.4 person-years)   (95% CI)                                                 
  --------------------- ------------------------------------------- ------------------------------------------ ---------- --------- ----- -------- ---------- --------- ------------------------
  Entire cohort                                                                                                                                                         

                        5279                                        2708.1                                     (2635.0,   2781.2)   964   1201.4   (1125.6,   1277.2)   0.46(0.43, 0.50)\*\*\*

  Age, 40-64 years^a^                                                                                                                                                   

                        2172                                        1868.7                                     (1790.1,   1947.3)   449   889.5    (807.3,    971.8)    0.43(0.39, 0.48)\*\*\*

  Age, 65-74 years^b^                                                                                                                                                   

                        1665                                        3732.1                                     (3552.8,   3911.4)   350   1607.1   (1438.7,   1775.5)   0.45(0.40, 0.50)\*\*\*

  Age, ≥75 years^c^                                                                                                                                                     

                        1442                                        4229.7                                     (4011.4,   4448.0)   165   2066.3   (1751.1,   2381.6)   0.51(0.43, 0.60)\*\*\*

  Female^d^                                                                                                                                                             

                        1874                                        2144.4                                     (2047.3,   2241.5)   423   1011.3   (914.9,    1107.6)   0.44(0.40, 0.50)\*\*\*

  Male^e^                                                                                                                                                               

                        3405                                        3166.2                                     (3059.8,   3272.5)   541   1408.5   (1289.8,   1527.1)   0.48(0.43, 0.52)\*\*\*
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Total follow-up 116228.5 person-year for patients not using statins and 50476.0 for patients using statins.

^b^Total follow-up 44612.9 person-year for patients not using statins and 21778.3 for patients using statins.

^c^Total follow-up 34092.2 person-year for patients not using statins and 7985.1 for patients using statins.

^d^Total follow-up 87389.9 person-year for patients not using statins and 41828.7 for patients using statins.

^e^Total follow-up 107543.7 person-year for patients not using statins and 38410.7 for patients using statins.

C.I.: confidence interval

HR: adjusted hazard ratio

†Main model was adjusted using propensity scores for age, sex, Charlson comorbidity index, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income.

###### 

Incidence Rate and aHRs of the All-Cancer Risk Associated with Statin Use During the Follow-Up Period in COPD Patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                  No. ofpatients   No. of person-years   No. of patients with\   Incidence Rate\             aHR\       *P* for\                            
                                                                   any cancer              (per 10^5^ person-years)\   (95%CI)    Trend                               
                                                                                           (95% CI)                                                                   
  ------------------------- ---------------- --------------------- ----------------------- --------------------------- ---------- ---------- ------------------------ ---------
  Total statin use                                                                                                                                                    

  Nonuser (\<28 cDDDs)      33716            194933.6              5279                    2708.1                      (2635.0,   2781.2)    1.00                     \<0.001

  User (≥28 cDDDs)          10086            80239.4               964                     1201.4                      (1125.6,   1277.2)    0.46(0.43, 0.50)\*\*\*   

  28-90 cDDDs               2346             17095.6               294                     1719.7                      (1523.2,   1916.3)    0.65(0.58, 0.73)\*\*\*   

  91-365 cDDDs              3215             24193.1               343                     1417.8                      (1267.7,   1567.8)    0.54(0.48, 0.60)\*\*\*   

  \>365 cDDDs               4525             38950.7               327                     839.5                       (748.5,    930.5)     0.32(0.29, 0.36)\*\*\*   

  Lipophilia statin use†                                                                                                                                              

  Nonuser (\<28 cDDDs)      35008            204288.0              5379                    2633.0                      (2562.7,   2703.4)    1.00                     \<0.001

  User (≥28 cDDDs)          8794             70885.0               864                     1218.9                      (1137.6,   1300.2)    0.57(0.53, 0.61)\*\*\*   

  28-90 cDDDs               2296             17069.8               270                     1581.7                      (1393.1,   1770.4)    0.67(0.59, 0.75)\*\*\*   

  91-365 cDDDs              3012             23258.7               332                     1427.4                      (1273.9,   1581.0)    0.65(0.58, 0.73)\*\*\*   

  \>365 cDDDs               3486             30556.4               262                     857.4                       (753.6,    961.3)     0.42(0.37, 0.48)\*\*\*   

  Hydrophilia statin use†                                                                                                                                             

  Nonuser (\<28 cDDDs)      39878            242812.7              5974                    2460.3                      (2397.9,   2522.7)    1.00                     \<0.001

  User (≥28 cDDDs)          3924             32360.4               269                     831.3                       (731.9,    930.6)     0.48(0.42, 0.55)\*\*\*   

  28-90 cDDDs               1122             8876.1                102                     1149.2                      (926.1,    1372.2)    0.62(0.51, 0.75)\*\*\*   

  91-365 cDDDs              1531             12432.2               94                      756.1                       (603.2,    909.0)     0.45(0.36, 0.55)\*\*\*   

  \>365 cDDDs               1271             11052.0               73                      660.5                       (509.0,    812.0)     0.40(0.31, 0.50)\*\*\*   

  Individual statin use\                                                                                                                                              
  (≥28 cDDDs )‡                                                                                                                                                       

  Simvastatin               3418             28625.0               257                     897.8                       (788.0,    1007.6)    0.55(0.49, 0.63)\*\*\*   

  Lovastatin                2109             18281.5               262                     1433.1                      (1259.6,   1606.7)    0.92(0.81, 1.04)         

  Atorvastatin              5484             44678.1               484                     1083.3                      (986.8,    1179.8)    0.59(0.54, 0.65)\*\*\*   

  Fluvastatin               1510             12855.7               151                     1174.6                      (987.2,    1361.9)    0.78(0.66, 0.92)\*\*     

  Pravastatin               1501             12654.5               122                     964.1                       (793.0,    1135.2)    0.66(0.55, 0.79)\*\*\*   

  Rosuvastatin              2741             22641.7               158                     697.8                       (589.0,    806.6)     0.42(0.36, 0.49)\*\*\*   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Main model was adjusted using propensity scores for age, sex, Charlson comorbidity index, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income.

†Lipophilia statins included simvastatin, lovastatin, atorvastatin, and fluvastatin. Hydrophilia statins include pravastatin and rosuvastatin.

‡HRs for individual statins were compared between users (≥28 cDDDs) and nonusers (\<28 cDDDs).

###### 

Sensitivity Analysis of aHRs of Statin Use for Reduction of the All-Cancer Risk.

  -------------------------------------------------------------------------------------------------------------------------------------------------
                                                Statin use\    P for Trend                                                                
                                                aHR (95% CI)                                                                              
  --------------------------------------------- -------------- ------------------------ ------------------------ ------------------------ ---------
  **Main model†**                               1.00           0.65(0.58, 0.73)\*\*\*   0.54(0.48, 0.60)\*\*\*   0.32(0.29, 0.36)\*\*\*   \<0.001

  **Additional covariates**‡                                                                                                              

  Main model + Nonstatin lipid-lowering drugs   1.00           0.66(0.59, 0.74)\*\*\*   0.56(0.50, 0.62)\*\*\*   0.34(0.30, 0.38)\*\*\*   \<0.001

  Main model + Metformin                        1.00           0.65(0.58, 0.73)\*\*\*   0.55(0.49, 0.61)\*\*\*   0.34(0.30, 0.38)\*\*\*   \<0.001

  Main model + ACEI                             1.00           0.66(0.59, 0.74)\*\*\*   0.58(0.52, 0.65)\*\*\*   0.38(0.34, 0.42)\*\*\*   \<0.001

  Main model + Aspirin                          1.00           0.66(0.59, 0.74)\*\*\*   0.57(0.51, 0.63)\*\*\*   0.35(0.32, 0.40)\*\*\*   \<0.001

  **Subgroup effects**                                                                                                                    

  Age, years                                                                                                                              

  40-64                                         1.00           0.65(0.55, 0.77)\*\*\*   0.50(0.43, 0.59)\*\*\*   0.29(0.25, 0.34)\*\*\*   \<0.001

  65-74                                         1.00           0.64(0.52, 0.79)\*\*\*   0.54(0.45, 0.64)\*\*\*   0.31(0.26, 0.37)\*\*\*   \<0.001

  ≥75                                           1.00           0.67(0.51, 0.87)\*\*     0.54(0.42, 0.71)\*\*\*   0.37(0.28, 0.49)\*\*\*   \<0.001

  Sex                                                                                                                                     

  Female                                        1.00           0.61(0.51, 0.74)\*\*\*   0.52(0.44, 0.62)\*\*\*   0.33(0.28, 0.39)\*\*\*   \<0.001

  Male                                          1.00           0.69(0.59, 0.80)\*\*\*   0.56(0.48, 0.64)\*\*\*   0.32(0.27, 0.37)\*\*\*   \<0.001

  CCI^+^                                                                                                                                  

  0                                             1.00           0.63(0.50, 0.80)\*\*\*   0.51(0.41, 0.64)\*\*\*   0.29(0.23, 0.36)\*\*\*   \<0.001

  1                                             1.00           0.65(0.53, 0.81)\*\*\*   0.56(0.46, 0.68)\*\*\*   0.32(0.26, 0.39)\*\*\*   \<0.001

  2                                             1.00           0.60(0.47, 0.77)\*\*\*   0.49(0.38, 0.63)\*\*\*   0.31(0.24, 0.40)\*\*\*   \<0.001

  ≥3                                            1.00           0.67(0.53, 0.85)\*\*     0.53(0.42, 0.66)\*\*\*   0.32(0.26, 0.41)\*\*\*   \<0.001

  Diabetes                                                                                                                                

  No                                            1.00           0.66(0.58, 0.76)\*\*\*   0.53(0.46, 0.61)\*\*\*   0.31(0.27, 0.36)\*\*\*   \<0.001

  Yes                                           1.00           0.60(0.48, 0.76)\*\*\*   0.52(0.43, 0.62)\*\*\*   0.32(0.26, 0.38)\*\*\*   \<0.001

  Dyslipidemia                                                                                                                            

  No                                            1.00           0.63(0.54, 0.73)\*\*\*   0.52(0.45, 0.61)\*\*\*   0.28(0.24, 0.33)\*\*\*   \<0.001

  Yes                                           1.00           0.67(0.55, 0.82)\*\*\*   0.54(0.46, 0.64)\*\*\*   0.36(0.31, 0.43)\*\*\*   \<0.001

  Hypertension                                                                                                                            

  No                                            1.00           0.73(0.62, 0.86)\*\*\*   0.53(0.44, 0.63)\*\*\*   0.28(0.23, 0.34)\*\*\*   \<0.001

  Yes                                           1.00           0.58(0.49, 0.69)\*\*\*   0.52(0.45, 0.60)\*\*\*   0.32(0.28, 0.37)\*\*\*   \<0.001

  Nonstatin lipid-lowering drugs                                                                                                          

  \<28 days                                     1.00           0.64(0.56, 0.73)\*\*\*   0.55(0.49, 0.63)\*\*\*   0.32(0.28, 0.37)\*\*\*   \<0.001

  28-365 days                                   1.00           0.89(0.65, 1.20)         0.58(0.44, 0.77)\*\*\*   0.36(0.27, 0.47)\*\*\*   \<0.001

  \>365 days                                    1.00           0.62(0.30, 1.28)         0.76(0.47, 1.23)         0.49(0.32, 0.76)\*\*     0.002

  Metformin                                                                                                                               

  \<28 days                                     1.00           0.65(0.56, 0.74)\*\*\*   0.55(0.48, 0.62)\*\*\*   0.31(0.27, 0.36)\*\*\*   \<0.001

  28-365 days                                   1.00           0.76(0.54, 1.07)         0.39(0.26, 0.58)\*\*\*   0.35(0.24, 0.52)\*\*\*   \<0.001

  \>365 days                                    1.00           0.77(0.54, 1.09)         0.81(0.64, 1.03)         0.45(0.36, 0.55)\*\*\*   \<0.001

  ACEI                                                                                                                                    

  \<28 days                                     1.00           0.65(0.54, 0.77)\*\*\*   0.54(0.45, 0.65)\*\*\*   0.38(0.30, 0.48)\*\*\*   \<0.001

  28-365 days                                   1.00           0.75(0.61, 0.93)\*       0.60(0.48, 0.76)\*\*\*   0.30(0.22, 0.41)\*\*\*   \<0.001

  \>365 days                                    1.00           0.81(0.64, 1.02)         0.81(0.67, 0.96)\*       0.51(0.43, 0.59)\*\*\*   \<0.001

  Aspirin                                                                                                                                 

  \<28 days                                     1.00           0.63(0.53, 0.74)\*\*\*   0.53(0.44, 0.62)\*\*\*   0.35(0.29, 0.42)\*\*\*   \<0.001

  28-365 days                                   1.00           0.69(0.55, 0.86)\*\*     0.65(0.52, 0.81)\*\*\*   0.30(0.23, 0.40)\*\*\*   \<0.001

  \>365 days                                    1.00           0.96(0.74, 1.25)         0.78(0.63, 0.96)\*       0.51(0.43, 0.61)\*\*\*   \<0.001
  -------------------------------------------------------------------------------------------------------------------------------------------------

\*p \< 0.05 \*\*p \< 0.01 \*\*\*p \< 0.001

aHR: adjusted hazard ratio

+CCI: Charlson comorbidity index

†Main model was adjusted using propensity scores for age, sex, Charlson comorbidity index, diabetes, hypertension, dyslipidemia, urbanization level, and monthly income.

‡Models were adjusted for covariates in the main model as well as each additional listed covariate.

[^1]: \*These authors contributed equally to this study (joint first authors).

[^2]: Competing Interests: The authors have declared that no competing interest exists.
